LAG3 Blockade Assay

Creative Biolabs is a first-class service provider focused on the antibody functional assays. In order to measure the activity and explore the mechanism of action (MOA) of antibodies or other biologics targeting LAG3, our talented scientists have developed effective LAG3 blockade assays based on reporter gene for global clients.

Introduction to LAG3

LAG3 (lymphocyte activation protein 3), also known as CD223, containing 4 extracellular Ig-like domains, belongs to immunoglobulin (Ig) superfamily. It is a surface molecule expressed on activated T cells, natural killer (NK) cells, B cells, and plasmacytoid dendritic cells (DCs). LAG3 has been revealed to exert a negative regulatory function in T cells. LAG3 binding its main ligand, MHC class II, negatively regulates cellular proliferation, activation, and homeostasis of T cells, with a similar function to CTLA-4 and PD-1. Besides, LAG3 has been revealed to play a role in the regulation of Treg suppressive function, the maturation, and activation of dendritic cells, as well as maintaining CD8 exhaustion in a tolerogenic state. Currently, a number of antibodies targeting LAG3 are in preclinical development, which takes the brakes off the anti-cancer immune response. Notably, LAG3 may be a better checkpoint inhibitor target than CTLA-4 and PD-1. Antibodies targeting CTLA-4 or PD-1 only activate effector T cells and do not suppress Treg activity, while antibodies targeting LAG3 can both activate T effector cells by down-regulating the LAG3 inhibiting signal into pre-activated LAG3⁺ cells and inhibiting induced Treg suppressive activity.

Fig.1 LAG-3 structure and ligands.¹

LAG3 Blockade Assay at Creative Biolabs

LAG3 blockade assay is a bioluminescent cell-based assay that overcomes the limitations of current methods (such as complex assay protocols, unqualified assay reagents, and independent of donor primary cells). This test can be used to measure the potency and stability of antibodies and other biologics targeting LAG3. Besides, it is also used to describe the MOA of biologics designed to block LAG3. Creative Biolabs has extensive experience in the antibody functional characterization. We are proud to offer high-quality LAG3 blockade assay services for global customers. Our services are characterized by:

• Excellent expert team for offering real-time technical guidance
• Advanced assay platform to promote the data output
• Timely data feedback to facilitate the process of your project

Popular LAG3 Products

With our extensive expertise in immunology and years of project experience, Creative Biolabs has engineered a range of effective kits to support the development of LAG3-based therapeutic solutions. Our EasyMeasure™ LAG-3/MHCII Blockade Bioassay Kit (CAT#: AK-LX013) and EasyMeasure™ LAG-3/MHCII Blockade Bioassay Kit-5XBP (CAT#: AK-LX030) are designed for easy and accurate assessment of LAG3/MHCII blockade activity. Additionally, we also provide specialized cell lines expressing LAG3 to facilitate the evaluation and development of anti-LAG3 antibody therapies.

Published Data

This study assessed the efficacy of the BsAb candidate in blocking immune checkpoint receptors PD-1 and LAG-3 on immune cells, particularly depleted T cells, as a potential strategy for cancer therapy. The results demonstrated that the BsAb candidate effectively inhibits the interaction between LAG-3 and MHC-II, as well as PD-1 and PD-L1, in a dose-dependent manner at the cellular level. The blocking capacity of the BsAb candidate is comparable to that of its parent antibodies.

Fig.2 The blocking properties of the BsAb candidate for LAG-3/MHC-II interaction.²

With the years of experience in the field of antibody functional assay, Creative Biolabs is specialized in offering the best LAG3 blockade assay service which is useful for functional analysis of antibody and other biologics targeting LAG3. For more detailed information, please feel free to contact us or directly sent us an inquiry.

References

1. Huo, Jin-Ling, et al. "The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application." Frontiers in Immunology 13 (2022): 956090.
   Distributed under Open Access License CC BY 4.0, without modification.
2. Shi, Ning, et al. "PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy." Frontiers in Immunology 13 (2022): 1047610.
   Distributed under Open Access License CC BY 4.0. The original image was modified by extracting and using part C, and the title was changed to "The blocking properties of the BsAb candidate for LAG-3/MHC-II interaction".

For Research Use Only.